Arteaga, C. L., Winnier, A. R., Poirier, M. C., Lopez-Larraza, D. M., Shawver, L. K., hurd, S. D. And Stewart, S. J. (1994) Cancer Res 54, 3758-3765.
Baer, R., A. T. Bankier, M. D. Biggin, P. L. Deiniger, P. J. Farrell, T. J. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Seguin, P. S. Tuffnell and B. G. Barrell. (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211.
Bargmann, C. I., Hung, M. C. & Weinberg, R. A. (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230.
Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., Mckenzie, S., Yin, S. & Bast, R. C. J. (1990) Cancer Res. 50, 4087-4091.
Bertram, J., Killian, M., Brysch, W., Schlingensiepen, K. H. & Kneba, M. (1994) Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucliotides. Biochim. Biophys. Res. Commm. 200, 661-667.
Cantley, L. C., Auger, K. R. Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R. & Soltoff, S. (1991) Oncogenes and signal transduction. Cell 64, 281-302.
Chen, H. and Hung, M.C. (1997) Involvement of co-activator p300 in the
transcriptional regulation the HER-2/neu gene. J. Biol. Chem, 272, 6101-
6104.
Dickman, S.（1998）Antibody stage a comeback in cancer treatment. Science 280, 1196-1197
Dougall, W. C., Qian, X., Peterson, N. C. Miller, M. J. Samanta, A. & Greene, M. I. (1994) The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9, 2109-2123.
Dsly, R. J.Binder, M. D. & Sutherland, R. L. (1994) Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9, 2723-2727.
D''souza, B. & Taylor-Papdimitriou, J. (1994) Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc. Natl. Acad. Sci. USA 91,7202-7206.
Durrant, L. G.（1997）Cancer vaccines. Anti-cancer drugs 8, 727-733.
Fahraeus, R. et al. (1988) Int. J. Cancer 42, 329-338
Falls, D. L., Rosen, K. M., Corfas, G., Lane, W. S. and Fischbach, G. D. (1993) ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72, 801-8015
Fisher, N., Jremmer, E., Lautscham, G., Mueller-Lanzsch, N. and Grasser, F. A. (1997) Epstein-Barr virus antigen 1 forms a complex with the nuclear transproter karyopherin α2. J. Biol. Chem. 272, 3999-4005.
Frappier, L. and Goldsmith, K. and Bendell, L. (1994) Stablization of the EBNA1 protein on the Epstein-Barr virus latent origin of DNA replication by a DNA looping mechanism. J Biol. Chem. 269, 1057-1062.
Gassmann, M., Casagranda, F. Orioll, D. Simon, H. Lai, C. Klein, R. & Lemke, G. (1995) Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394.
Gee, J. E. Yen, R. L., Hung M. C. & Hogan, M. E. (1994) Triple formation at the rat neu oncogene promoter. Gene 149, 109-114.
Gonzalez, G. A. and Montminy, M. R. (1989) Cyclic AMP stimulates somatostain gene transcription by phosphorylation of CREB at serine. Cell 59, 675-680.
Gorlich, D. and Mattaj, I. W. (1996) Nucleocytoplasmic Transport. Science 271, 1513-1518.
Gotoh, N., Tojo, A., Muroya, K., Hashimoto, Y., Hattori, S., Nakamura, S., Tskenawa, T., Yazaki, Y. & Shibuya, M. (1994) Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity. Proc. Natl. Acaad. Sci. USA 91, 167-171.
Gullick, W. J.,(1990) The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast. Int. J. Cancer (suppl.) 5, 55-61.
Gullick, W. J., Love, S. B., Wreght, C. (1991) c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and univolved lymph nodes. Br. J. Cancer 63, 434-440.
Gusterson, B. A., Gelber, R. D., Coldhirsch, A., Price, K. N., Save-Soderborgh, J.( 1992) Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 10, 1049-1056.
Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Michak, R. P. And Shawver, L. K.(1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis- diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51, 4575-4580.
Hearing, J. C. and Levine, A. J. (1985) The Epstein-Barr virus nuclear antigen (BamHI K antigen) is a single-strand DNA binding phosphoprotein. J. Virol. 145, 105-116.
Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Hinzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., Sgepard, H. M., Kuang, W. J., Wood, W. I., Goeddel, D. V. & Vandlen, R. L. (1992) Identification of Heregulin, a specific activator of p185erbB2. Science 256, 1205-1210.
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M. and Ullrich, A. (1989) Monoclonal antibody has antiproliferative effects in vitro and senitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9, 1165-1172.
Hung, M. C., Yan, D. H. & Zhao, X. (1989) Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc. Natl. Acad. Sic. USA 86, 2545-2548.
Hunter, T., and Karin, M. (1992) The regulation of transcription by
phosphorylation. Cell 70, 375-387.
Indolfi, C., Chiariello, M. and Avvedimento, E. V. (1996) Selective gene therapy for proliferative disorders: Sence and Antisense. Nature Medicine. 2 (6), 634-635.
Inoue, N., Harada, S., Honma, T., Kitamura, T. and Yanagi, K. (1991) The domain of Epstein-Barr virus nuclear antigen 1 essential for binding to oriP region has a sequence fitted for the hypothetical basic-helix-loop-helix structure. Virology 182, 84-93.
Kao, M. C.,Law, S. L., Chuang, T. C. and Lin, Y. S. (1998) In vitro gene transfer in mammalian cells via a new cationic liposome formulation. Oncology report 5, 625-629.
Kameda, T., Yasui, W., Yoshida, K., Tsujino, T., Nakyama, H., Ito, M., Ito, H. & Tahara, E. (1990). Expression of ERBB2 in human gastric carcinomas: Relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 50, 8002-8009.
Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Green, M. t., Torney, I. & Robinson, R. A. (1990) p185neu expression in human lung adenocarcinomas predicts shortened survial. Cancer Res. 50, 5184-5191.
Kita, Y. A. Barff, J., Luo, Y., Wen, D., Brankow, D., Hu, S., Liu, N., Prigent, S. A., Gullick, W. J. & Nicolson, M. (1994) NDF/heregulin stimulates the phosphorylation of HER3/erbB-3. FEBS 349, 139-143.
Lee, K. F., Simon, H., Chen, H., Bastes, B., Hung, M. C. & Hauser, C. (1995) Reguirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398.
Lemmon, M. A. and Schlessinger J. (1994) Regulation of signal transduction and signal diversity by receptor oligomerzation. TIBS 19, 459-463.
Liu, G. Y.: Transcriptional repression of the neu oncogene by two peptides derived from the SV40 large T antigen. Master thesis (adviser: Kao, M. C. ), National Defense Medical Center, Taipei, Taiwan, 1995.
Lin, C. S., Chen, J. Y., Yang, C. S.and Wang, W. B. (1999) Epstein-Barr virus EBNA-2 retard cell growth by post-translational modification of p53 and induction of p21WAF1. Second NHRI Conference on Tumor Associated Herpesviruses. Program and Abstracts. p32.
Mackey, D., Middleton, T. and Sugden, B. (1995) Multiple regions within EBNA1 can link DNAs. J. Virol 69, 6199-6208.
Marchionni, M. A., Goodeari, A. D. J., Chen, M. S., Bermingham-Mc Donogh, O., Sudhalter, J., Kobayashi, K., Wroblewski, D., Lynch, C., Baldassare, M., Hiles, I., Davis, J. B., Hsuan, J. J., Totty, N. F., Otsu, M., McBurney, R. N., Waterfield, M. D., Stroobant, P. & Gwynne, D. (1993) Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362, 312-318.
Marchionni, M. A. (1995) neu tack on neuregulin. Nature 378, 334-335.
Matin, A. & Hung, M. C. (1993) Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ. 4, 1-6.
Matin, A. & Hung, M. C. (1994) The retinoblastoma gene products, Rb, represses neu expression through two regions within the neu regulatory sequence. Oncogene 9, 1333-1339.
Matin, A., Xie, Y., Kao, M. C. & Hunag, M. C. (1995) Rodent p53 suppersses the transforming activity of the activated neu oncogene by modulating the basal promoter activity of neu. International J. Oncol. 6, 1087-1092.
Mizuguchi, G., Kanei-Ishii, C., Tokahashi, T., Yasulawa, T., Nagase, T., Horikoshi, N., Yamamoto, T. & Ishii, S. (1995) c-Myb repression of c-erbB2 Trans cription by direct binding to the c-erbB2 promoter. J. Biol. Chem. 270, 9384-9389.
Molina, H., Brenner, C., Jacobi, S., Gorka, J., Carel, J. C., Kinoshita, T. and Holers, V. M.(1991) Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD2)using human-mousr chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J. Biol. Chem. 266, 12173-12179.
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M. and Henderson, I. C. (1994) N. Engl. J. Med. 330, 1260-1266.
Noonberg, S. B., Scott, G. K., Hunt, C. A., Hogan, M. E. & Benz, C. C. (1994) Inhibition of transcription factor binding to the HER2 promoter by triple-forming oligodeoxyribonucleotides. Gene 149, 123-126.
Palowman, G. D., Green, J. M., Culouscou, J. M., Cariton, G. W., Rothwell, V. M. & Buckiey, S. (1993) Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 . Nature 366, 473-475.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., Parahadjopulos, D. & Benz, C. C. (1995) Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92, 1327-1331.
Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B. And Slamon, D. J. (1994) oncogene 9, 1829-1838.
Polvino-Bodnar, M. and Schaffer, P. A. (1992) DNA binding activity is required for EBNA1-depwndent transcripation activation and DNA replication. Virology 187, 591-603.
Qian, X., Levea, C. M., Freeman, J. K., Dougall, W. C. & Greene, M. I. (1994) Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kianse activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91, 1500-1504.
Rawlins, D. R., Milman, G., Hayward, S. D. and Hayward, G. S. (1985) Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA1) to clustered site in the plasmid maintenance region. Cell. 42, 859-868.
Reedman, B. M. and Klein, G. (1973) Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell line. Int. J Cancer 11, 499-520.
Rowe, D. T., Evan, G. I., Wallace, L.E., Farrell, P. J. and Rickinson, A. B. (1986) Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt''s lymphoma cells. EMBO J 5, 2599-2607
Salmons, B. & Gunzburg, W. H. (1993) Targeting of retroviral vectors for gene therapy. Human Gene Therapy 4, 129-141.
Salmon, D. J.,Clark, G. M., Wong, S. G., Levin, W. J., Ullrch, A. And McGuir, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235, 177-182.
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., wong, S. G., Keith D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. And Press, M. F. (1989) Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
Samanta, A., Levea, C. M., Dougall, W. C., Qian, X. & Greene, M. I. (1994) Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc. Natl. Acad. Sci. USA 91, 1711-1715.
Sample, J., Brooks, L., Sample, C., Yoing, L., Rowe, M., Gregory, C., Rickinson, A. and Kieff, E. （1991）Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc. Natl Acad. Sci. USA 88, 6343-6347.
Sample, J., Daniel Henson, E. B. and Sample, C. （1992）The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol 66, 4654-4661.
Schaefer, B., Woisetschlaeger, M., Strominger, J. and Speck, S.（1991）Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Natl Acad. Sci. USA 88, 6550-6561.
Schneider, P. M., Hung, M. C. Chiocca, S. M., Manning, J., Zhao, X., Fang, K. & Roth, J. A. (1989) Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer Cancer Res. 49, 4968-4971.
Shepard, H. M., Lewis, G. D., Sarup, J. C. (1992) Monoclonal antibody therapy of human cancer: taking the HER-2 protooncogene to the clinic. J Clin Immunol 11, 117-127
Sliwlowski, M. X., Schaefer, G., Alita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens A., Fendly, B. M., Cerione, R. A., Vandlen, R. L. & Csrraway, K. L. (1994) Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for Heregulin. J. Biol. Chem. 269, 14661-14665.
Snudden, D. K., Hearing, J., Smith, P. R., Grasser, F. A. and Griffin, B. E. (1994) EBNA1, the major nuclear antigen of Epstein-Barr virus, resembles ''RGG'' RNA bindimg protein.EMBO.13, 4840-4847.
Smith, P. R. and Griffin, B. E.（1992）J. Virol. 66, 706-714.
Suen, T. C. & Hung, M. C. (1990) Multiple cis- and trans-acting elements involved in regulation of the neu gene. Mol. Cell. Biol. 10, 6306-6315.
Suen, T. C. & Hung, M. C. (1991) c-Myc reverses neu-induced transformed morphology by transcriptional repression. Mol. Cell. Biol. 11, 354-362.
Tan, M., Yao, J. and Yu, d. (1997) Overexpression of the c-erbB2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.Cancer Res 57, 1199-1205.
Ueki, N., Oda, T., Kondo, M., Yano, K., Noguchi, T. and Muramatsu, M. (1998) Selection system for genes encoding nuclear-targeting proteins. Nature Biotechnology 16, 1338-1342.
Ueno, N. T., Yu, D. and Hung, M. C. （1997）Chemosensitization of HER-2/neu-overexpressing human breast cancer cell to paclitaxel（Taxol）by adenovirus type 5 E1A. oncogene 15, 953-960.
Wen, D., Peles, E., Cupples, R., Suggs, S. V., Bacus, S. S., Luo, Y., Trail, G., Hu, S., Silbiger, S. M., Levy, R. B., Koski, R. A., Lu, H. S. & Yarden, Y. (1992) Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and immunoglobulin homology unit. Cell 69, 559-572.
Williams, T. M., Weiner, D. W., Greene, M. I. and Maguire, H. C., Jr. (1991) Pathobiology 59, 46-52.
Xie, Y. & Hung, M. C. (1994) Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem. Biophys. Res. Commun. 203, 1589-1598.
Yamamoto, T., Ikawa, S., akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T. & Toyoshima K. (1986) Similarity of protein encoded by the human c-erbB2 gene to epidermal growth factor receptor. Nature 319, 230-234.
Yates, J., Warren, N., Reisman, D. and Sugden, B. (1984) A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. USA. 81, 3806-10.
Yu, D. and Hung M. C. (1991) Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6, 1191-1196
Yu, D. and Hung M. C. (1995) Molecular basis of oncology-chpater 5: The HER-2/neu gene in human cancer. Blackwell Science, 131-162.
Yu, D., Jing, T., Lin, B., Yao, J.,Tan, M., Mcdonnell, T.J. and Hung, M.C. (1998) Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21cip1, which inhibits p34cdc2 kinase. Molecular Cell 2, 581-591
Yu, D., Liu, B., Tan, M., Li, J., Wang, S-S and Hung, M. C. (1996) Overexpression of c-erbB-2/neu in braest cancer cels confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13, 1359-1365.
Yu, D., Matin, A., Hinds, P. W., and Hung, M.C. (1994) Transcriptional regulation of neu by RB and E1A in Rat-1 cells. Cell Growth & Differentition., 5, 431-438.
Yu, D., Suen, T. C., Yan, D. H., Chang, L. S. & Hung, M. C. (1990) Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. Natl. Acad. Sci. USA 87, 4499-4503.
Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A. & Yoshinaga, S. K. (1996) Transformation of NIH3T3 cells by HER3 or HER4 Recepfors Requires the Presence of HER1 or HER2. J. Biol. Chem. 271, 3884-3890.
Zhang, L., Chang, C. J., Bacus, S. S. & Hung, M.C. (1995) Suppressed transformation and differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 55, 3890-3896.
莊子超 (1996) 國防醫學院生物化學研究所碩士論文：發展一新微脂粒基因傳送系統及猿病毒突變型腫瘤抗原抑制 neu 致癌基因表現之分析。魏宗德 (1997) 國防醫學院生物化學研究所碩士論文：非洲淋巴細胞瘤病毒胞核抗原-1 抑制致癌基因 HER-2/neu 之轉錄表現。李瓔祝 (1998) 國防醫學院生物化學研究所碩士論文：探討 EB 病毒核抗原-1 抑制神經膠原致癌基因表現的順式作用序列。胡誌麟( 1998) 國防醫學院生物化學研究所碩士論文：非洲淋巴細胞瘤病毒胞核抗原-1 氮端八十六個胺酸區域可為神經膠原致癌基因的轉形抑制劑。